Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Why the medtech contract manufacturing M&A trend isn’t slowing down
Consolidation is increasingly shaping the medical device industry, but what about players on the other side of the fence? Medtech contract manufacturing partners to OEMs are seeing their own abundance of M&A as larger players look to expand their influence and keep up with increasing demand. Read more
4. Rebiotix launches late-stage superbug trial for microbiome-based drug
Rebiotix isn’t a traditional drugmaker. Its products are alive.
The 32-person company, based in Roseville, Minn., is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes. Read more
3. Aum Cardiovascular wins FDA clearance for Cadence heart device
Aum Cardiovascular said today that it won 510(k) clearance from the FDA for its Cadence device, which is designed to detect heart murmurs.
Cadence works by applying an algorithm to the acoustic signature of heart murmurs in the primary care setting, allowing physicians to diagnose the condition without resorting to expensive CT, MRI or ultrasound scans. Read more
2. Nevro ticks down despite Q2 sales beat
Nevro shares ticked down yesterday despite second-quarter revenues that came in well ahead of analysts’ expectations and just beat the company’s own forecast.
Redwood City, Calif.-based Nevro posted losses of -$11.5 million, or -40¢ per share, on sales of $78.02 million for the 3 months ended June 30, widening its losses by 32.9% on sales growth of 40.8% compared with Q2 2016. Read more
1. AirXpanders raises $15m debt round
AirXpanders said yesterday that it raised $15 million in debt financing from Oxford Finance, sending share prices up today in Australia.
The Palo Alto-based company makes the AeroForm tissue expander for post-mastectomy breast reconstruction. The device is designed to expand and stretch the skin and underlying muscle prior to a permanent breast implant using small amounts of CO2 up to 3 times a day. Read more
